Phenominer Database Results (9 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 22.6 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69396 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 32.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69427 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 2.7 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69428 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 22.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69414 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 18.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 31days 69395 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69412 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 16.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69413 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 90.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69394 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 30.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69426 892